However, depletion of B cells by anti-CD20 antibodies in melanoma patients decreases tumor-associated inflammation and CD8+ T cell numbers and CD138+ plasmablast-like cells increase T cell activation in response to anti-PD-1 blockade in vitro. The gene discussed is CD8A; the disease is melanoma.